FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.
What happened
FDA inspected the Orlando facility from October 27 to 31, 2025. It found that batches of topical OTC drugs had failed microbiological tests, including batches with Staphylococcus aureus and Pseudomonas aeruginosa, but the company released them based on passing retests without thorough investigations. FDA also found the company had not validated its rapid microbiological test methods and had not adequately tested incoming high-risk components.
What FDA found
The company released batches after failed microbial tests by relying on passing retests without a thorough investigation into the cause.
21 CFR 211.192The company did not validate its rapid microbiological test methods to show they were suitable and equivalent to United States Pharmacopeia methods.
21 CFR 211.165(e)The company did not perform at least one identity test on each incoming component lot and did not establish the reliability of supplier certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not test each lot of certain high-risk components for a hazardous impurity using the United States Pharmacopeia limit test.
21 CFR 211.84(d)(1) and 211.84(d)(2)
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions and also asks for several assessments, a retrospective review of failed microbial results, test method validation, supplier and component reviews, and risk assessments; high-risk component test results are due within 30 calendar days.
Who should pay attention
- brands that buy topical OTC drugs from this contract manufacturer
- companies relying on supplier certificates for high-risk components
- quality teams managing microbial test methods and failed-result investigations
This is a summary. Read the original letter on fda.gov.